Clinical trial NCT02787616: Genetic Basis of Rosacea
Official title: Validation of Candidate Rosacea Genes By Targeted Interrogation of Alleles and Assessment of Rosacea Co-morbidities
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rosacea
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2016-06-01
Enrollment: 306
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 300 individuals will be enrolled, 150 with dermatologist verified rosacea and 150 without rosacea.

Brief summary: Rosacea is a common disease characterized by inflammation and vascular abnormalities of the facial skin and ocular surface. The exact pathogenesis of papulopustular rosacea is not well understood and current methods to treat this disease are often unsatisfactory. The purpose of this study is to develop gene expression profiles of papulopustular rosacea compared to those of normal skin. The investigators hope to better understand the abnormal gene functions that might contribute to this condition. This understanding may lead to the development of additional and better treatments for rosacea.


Eligibility criteria: Eligibility Criteria for Rosacea Group:

Inclusion criteria for rosacea participants:

1. Clinical signs and symptoms of rosacea (papulopustular or erythrotelangiectatic subtypes) present at enrollment as determined by the investigator
2. All four grandparents of European descent
3. Fitzpatrick skin type I or II
4. Age 18 years or older

Exclusion criteria for rosacea participants:

1. Unable or unwilling to provide written informed consent
2. Concomitant facial or medical condition that obscures diagnosis of rosacea (such as malar erythema from lupus erythematosus)
3. Acne vulgaris
4. Unable or unwilling to provide peripheral blood sample (a few teaspoons)
5. Inability for investigator to verify rosacea diagnosis on clinical examination due to rosacea treatment(s) leading to complete lack of signs and symptoms (such prior laser treatments, systemic tetracycline usage, etc.)
6. Use of topical prescription medications or procedures to the face within one month of enrollment
7. Women who are pregnant or lactating

Eligibility Criteria for Non-Rosacea Group:

Inclusion criteria for control participants:

1. No history of rosacea
2. No clinical signs or symptoms of rosacea
3. No family history of rosacea
4. All four grandparents of European descent
5. Fitzpatrick skin type I or II
6. Age 18 years or older

Exclusion criteria for control participants:

1. Unable or unwilling to provide written informed consent
2. Acne vulgaris
3. Unable or unwilling to provide peripheral blood sample (a few teaspoons)
4. Women who are pregnant or lactating
5. Use of topical prescription medications or procedures to the face within one month of enrollment
6. Skin conditions that might interfere with interpretation of procedure results (at the discretion of the investigator)

Primary outcomes:
measure: Targeted interrogation of alleles and assessment of rosacea co-morbidities.
timeFrame: Up to 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Redwood City
country: United States
facility: Stanford Dermatology
state: California
Study officials:
References: